Drugs / HDV Insulin Lispro
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03096392 | Apr → Nov 2017 | type 1 diabetes mellitus | Diasome Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02794155 | Jun 2016 → Apr 2018 | type 1 diabetes mellitus | Diasome Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDV Insulin Lispro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02794155 ↗ |
| Modality | Protein / enzyme biologic | “Hepatic-directed vesicle insulin (HDV) uses a hepatocyte-targeting moiety passively attaching free insulin” PMID 31551249 ↗ Sep 2019 |
| Route | Subcutaneous | “HDV Insulin Lispro subcutaneous, pre-prandial dosing, 26 week treatment period” NCT02794155 ↗ |